EOD Primary Tumor

Notes

**Note 1:** Islets of Langerhans are distributed throughout the pancreas; an islet tumor is coded according to the subsite of the pancreas in which the tumor arises if the information is available. **Note 2:** The terms “abutment,” “abut(s),” “encases,” or “encasement” of the major blood vessels can be interpreted as involvement of these structures.
Code Description SS2018 T
000 In situ: Noninvasive; intraepithelial - High-grade pancreatic intraepithelial neoplasia (PanIn-3) - Intraductal papillary mucinous neoplasm with high grade dysplasia - Intraductal tubulopapillary neoplasm with high grade dysplasia - Mucinous cystic neoplasm with high-grade dysplasia IS
100 Any size tumor - Confined to pancreas - Localized, NOS L
500 Any size tumor All sites - Ampulla of Vater - Duodenum - Extrahepatic bile duct(s) - Portal vein - Peripancreatic tissue, NOS - Stomach - Superior mesenteric vein Head of pancreas - Adjacent stomach - Gastroduodenal artery - Transverse colon, including hepatic flexure Body and/or tail of pancreas - Spleen - Splenic artery/vein - Splenic flexure Fixation to adjacent structure(s), NOS RE
600 All Sites - Aortic artery - Celiac [axis] artery - Common hepatic artery - Superior mesenteric artery Further contiguous extension to other major arteries RE
700 All sites - Adrenal gland/suprarenal gland - Gallbladder - Kidney - Liver, including porta hepatis - Mesenteric fat - Mesentery - Mesocolon - Peritoneum - Retroperitoneum - Small intestine (excluding duodenum, see code 500) - Ureter Further contiguous extension to other organs Head of pancreas - Colon (other than transverse colon including hepatic flexure, see code 500) - Omentum - Spleen Body and/or tail of pancreas - Colon (other than splenic flexure) - Diaphragm D
800 No evidence of primary tumor U
999 Unknown; extension not stated Primary tumor cannot be assessed Not documented in patient record Death Certificate Only U
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998 (2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. (3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL) (4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 3-30 (5) Kakar, S., Pawlik, T.M., Vauthey, J.N., et al. **Exocrine Pancreas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 337-347